Immunity at the Gate of Entrance; Vaccines against Respiratory Viruses such as Influenza, Corona, and RSV 2.0

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (15 October 2021) | Viewed by 363

Special Issue Editor


E-Mail Website
Guest Editor
Department for Immune Mechanisms, Centre for Infectious Disease Control, National Institute of Public Health and the Environment (RIVM), Bilthoven, The Netherlands
Interests: influenza; resident t-cells; universal vaccines; animal models; pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Most vaccines induce systemic immunity through intramuscular administration. This route of vaccination disregards a very potent part of the immune system—local adaptive immunity. There are numerous reports that show that mucosal antibodies (IgA), resident memory T-cells (Trm), and memory B-cells in mucosal associated lymphoid tissue play an important role in protection against respiratory viruses at the gate of entrance. Despite this, a limited number of locally administered respiratory vaccines are available.

Challenges include adjuvation, formulation, and induction of long-lasting immunity. For influenza (and possibly SARS-CoV-2) in particular, a broadly reactive immunity is a challenge, and Trm and local stem antibodies may be an answer. For corona, RSV, and influenza immunity, longevity is a holy grail. Therefore, research that provides insight into local immune parameters that correlate with protection against respiratory viruses or that are shown to be long-lasting is welcomed. Immune induction may be through vaccination, using adjuvants and formulation techniques to steer the immune response or by immune transfer techniques, etc. when this leads to a better understanding of potent vaccine targets.

Combining insights and strategies developed for different respiratory viruses into one Special Issue encourages cross-pollination of the different research fields and would advance the development of locally administered respiratory vaccines overall.

Dr. Jorgen De Jonge
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop